TY - JOUR
T1 - Invasive lobular carcinoma
T2 - an understudied emergent subtype of breast cancer
AU - Mouabbi, Jason A.
AU - Hassan, Amy
AU - Lim, Bora
AU - Hortobagyi, Gabriel N.
AU - Tripathy, Debasish
AU - Layman, Rachel M.
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/6
Y1 - 2022/6
N2 - Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all breast cancer cases. Although most ILCs are of the luminal A intrinsic subtype, with favorable prognostic features, conflicting literature data are available on their outcomes compared to IDC with reports suggesting a higher risk of distant recurrence after 10 years. Historically, studies have combined ILC and IDC, with outcomes largely driven by the behavior of IDC given that it represents 90% of breast cancers. However, over the past 5 years, reports of several studies aimed at understanding ILC at the clinical, cellular, and molecular levels have been published, showing that IDC and ILC are distinct entities. In this review, we highlight the unique characteristics of ILC and describe the need for dedicated ILC clinical trials.
AB - Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all breast cancer cases. Although most ILCs are of the luminal A intrinsic subtype, with favorable prognostic features, conflicting literature data are available on their outcomes compared to IDC with reports suggesting a higher risk of distant recurrence after 10 years. Historically, studies have combined ILC and IDC, with outcomes largely driven by the behavior of IDC given that it represents 90% of breast cancers. However, over the past 5 years, reports of several studies aimed at understanding ILC at the clinical, cellular, and molecular levels have been published, showing that IDC and ILC are distinct entities. In this review, we highlight the unique characteristics of ILC and describe the need for dedicated ILC clinical trials.
KW - CDH1
KW - Endocrine therapy
KW - ER+
KW - Estrogen receptor positive
KW - HR+
KW - ILC
KW - Invasive lobular carcinoma
KW - Review article
UR - http://www.scopus.com/inward/record.url?scp=85127239231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127239231&partnerID=8YFLogxK
U2 - 10.1007/s10549-022-06572-w
DO - 10.1007/s10549-022-06572-w
M3 - Review article
C2 - 35347549
AN - SCOPUS:85127239231
SN - 0167-6806
VL - 193
SP - 253
EP - 264
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -